Cargando…

Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC

Dysfunction of the mitochondria is well-known for being associated with cancer progression. In the present study, we analyzed the mitochondria proteomics of lung cancer cell lines with different invasion abilities and found that EGFR is highly expressed in the mitochondria of highly invasive non-sma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Che, Ting-Fang, Lin, Ching-Wen, Wu, Yi-Ying, Chen, Yu-Ju, Han, Chia-Li, Chang, Yih-leong, Wu, Chen-Tu, Hsiao, Tzu-Hung, Hong, Tse-Ming, Yang, Pan-Chyr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741934/ https://www.ncbi.nlm.nih.gov/pubmed/26497368

Ejemplares similares

MDA-9/Syntenin-Slug transcriptional complex promote epithelial-mesenchymal transition and invasion/metastasis in lung adenocarcinoma
por: Wang, Lu-Kai, et al.
Publicado: (2015)

N‐glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC
por: Han, Chia‐Li, et al.
Publicado: (2021)

Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis
por: Hung, Pei-Fang, et al.
Publicado: (2019)

Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
por: Wu, Shang-Gin, et al.
Publicado: (2017)

N6-Isopentenyladenosine Impairs Mitochondrial Metabolism through Inhibition of EGFR Translocation on Mitochondria in Glioblastoma Cells
por: Pagano, Cristina, et al.
Publicado: (2022)

The Motor Protein KIF14 Inhibits Tumor Growth and Cancer Metastasis in Lung Adenocarcinoma
por: Hung, Pei-Fang, et al.
Publicado: (2013)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway
por: Hou, Xiaoying, et al.
Publicado: (2018)

Corrigendum: Daxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1α/HDAC1/Slug axis
por: Lin, Ching-Wen, et al.
Publicado: (2017)

PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs
por: Chen, Chia-Hung, et al.
Publicado: (2021)

Monocarboxylate Transporter 4 Is a Therapeutic Target in Non-small Cell Lung Cancer with Aerobic Glycolysis Preference
por: Kuo, Ting-Chun, et al.
Publicado: (2020)

Sulforaphane attenuates EGFR signaling in NSCLC cells
por: Chen, Chi-Yuan, et al.
Publicado: (2015)

High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers
por: Chang, Yih-Leong, et al.
Publicado: (2017)

TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma
por: Lin, Jau-Chen, et al.
Publicado: (2012)

Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC
por: Cheng, Fang-Ju, et al.
Publicado: (2020)

Phosphorylation of LCRMP-1 by GSK3β Promotes Filopoda Formation, Migration and Invasion Abilities in Lung Cancer Cells
por: Wang, Wen-Lung, et al.
Publicado: (2012)

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
por: Noronha, Vanita, et al.
Publicado: (2014)

The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Aldosterone Suppresses Endothelial Mitochondria through Mineralocorticoid Receptor/Mitochondrial Reactive Oxygen Species Pathway
por: Peng, Shih-Yuan, et al.
Publicado: (2022)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis
por: Chang, Wei-Yuan, et al.
Publicado: (2018)

Achyranthes bidentata polysaccharide can safely prevent NSCLC metastasis via targeting EGFR and EMT
por: Zhong, Chunlian, et al.
Publicado: (2020)

Antimicrobial Peptide TP4 Targets Mitochondrial Adenine Nucleotide Translocator 2
por: Su, Bor-Chyuan, et al.
Publicado: (2020)

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
por: Kudo, Kenichiro, et al.
Publicado: (2020)

Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC
por: Lin, Chia-Ying, et al.
Publicado: (2019)

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)

EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer
por: Wu, Pei-Shan, et al.
Publicado: (2023)

An IL-17-EGFR-TRAF4 axis contributes to the alleviation of lung inflammation in severe influenza
por: Dutta, Avijit, et al.
Publicado: (2023)

Exosomal long noncoding RNA MLETA1 promotes tumor progression and metastasis by regulating the miR-186-5p/EGFR and miR-497-5p/IGF1R axes in non-small cell lung cancer
por: Hsu, Xiu-Rui, et al.
Publicado: (2023)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Metachronous Brain Metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis
por: Ouyang, Wen, et al.
Publicado: (2020)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
por: Wu, Wen-Shuo, et al.
Publicado: (2014)

RT-based combination therapy for brain metastasis from NSCLC with non-EGFR mutation/ALK gene rearrangement: A network meta-analysis
por: Wu, Min, et al.
Publicado: (2022)

Author Correction: Achyranthes bidentata polysaccharide can safely prevent NSCLC metastasis via targeting EGFR and EMT
por: Zhong, Chunlian, et al.
Publicado: (2020)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: A single institution retrospective analysis
por: Chen, Hualin, et al.
Publicado: (2018)

Unexpected responses to EGFR inhibition in NSCLC
por: Stella, Giulia M., et al.
Publicado: (2015)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFR(mut) NSCLC in diagnosis, follow-up and treatment
por: Lüke, Florian, et al.
Publicado: (2018)

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations
por: Wei, Xue-Wu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eh9rnft7v0vlfir30erca0n7jj